Tuberculosis Drug Discovery and Development 2019 (MDPI - Multidisciplinary Digital Publishing Institute, 2020)
Keywords: anti-TB drug pipeline; anti-virulence compounds; antibiotic; antimicrobial drug resistance (AMR); antimycobacterial; antituberculosis agents; artificial pneumothorax; BCG; bedaquiline; Biology, life sciences; biomarkers; Carlo Forlanini; caseum; cell envelope; clinical studies; clinical trial; CTVD; delpazolid; discovery; DNA gyrase; dormancy; DprE1 inhibitor; drug combination; drug development; drug discovery; drug resistance; drug-drug interactions; EDCTP; electron transport chain; energy metabolism; genomics; granulomas; host-directed therapy; IAVI; in vitro; in vivo; isoniazid; lead generation; lipidomics; macozinone; Mathematics and Science; mechanism of action; mechanisms of resistance; metabolomics; MID3; mode of action; multi-drug resistance; mutations; mycobacteria; mycobacterium; Mycobacterium tuberculosis; n/a; oxidative phosphorylation; pharmacodynamics; pharmacokinetics; phenotypic screening; PknB; PknG; post-treatment sequelae; privileged targets; promiscuous targets; proteomics; pulmonary rehabilitation; Q203; Reference, Information and Interdisciplinary subjects; Research and information: general; rifampin; structure-based drug design; surgery; target; target identification; target-based drug design; target-based screening; TBVI; toxicity; transcriptomics; tuberculosis; tuberculosis treatment; tuberculosis vaccines